UPDATE: Phase 1 GenSci143 Trial Set To Start By The End of December

We have already talked about it here, GenSci143, is a novel bispecific antibody-drug conjugate targeting B7-H3 and PSMA, and a phase 1 trial is set to begin first-in-human clinical trials soon (est. date December 20) in participants with advanced solid tumors, including metastatic castration-resistant prostate cancer.

Recent regulatory approvals were granted by the U.S. FDA and China’s National Medical Products Administration in October and November 2025, authorizing the initiation of a Phase I dose-escalation study to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy.

This dual-target construct aims to overcome tumor heterogeneity and resistance seen with single-target therapies by simultaneously engaging two validated antigens expressed on tumor cells. Preclinical studies have shown promising antitumor activity and a favorable safety profile, supporting its advancement into clinical testing.

Clinical trial.